PATENT CLAIM ANALYSIS

Application Number: 16220512
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["544", "231000"]

Abstract:
The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

Claim (Index 16):
A method for the treatment of a condition selected from Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2, the method comprising administering to a mammal in need thereof an effective amount of a compound, which is\n (4S)-3-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1\u2032-methyl-spiro[2,3-dihydropyrano[2,3-b]pyridine-4,6\u2032-hexahydropyrimidine]-2\u2032,4\u2032-dione, or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15869268', '15707848', '15245955', '15283010', '15205466']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8016045455794313
- 35 USC 102 Novelty (BERT): 0.6165529101171442
- Combined Prediction Score: 0.7830993820332026
- Mean Citation Score: 496.70262
- Max Citation Score: 607.0468
- Similarity Product: 492.9218788679122

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test